[ A21-147] Angiotensin II acetate (refractory hypotension in distributive shock) - Addendum to Commission A21-95

Last updated 06.01.2022

Project no.:

Commission awarded on 23.11.2021 by the Federal Joint Committee (G-BA).

Report type:

Commission completed

Drug Assessment

Application field:
Heart and circulation


Refractory hypotension in adults with septic or other distributive shock who remain hypotensive despite appropriate restoration of volume and use of catecholamines or other available vasoconstrictive therapies

Result of dossier assessment:

Unchanged after addendum:
Added benefit not proven.


If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.

Federal Joint Committee (G-BA)

2022-01-06 A G-BA decision was published.

G-BA documents on this decision


Info Service (German)

Subscribe to daily updated information on projects, calls for tender, current vacancies and events as well as our press releases.


Contact form

Questions about commissions, publications and press releases can be sent to us via this form.

Contact form